Clinical Trial

A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-19; most recent amendment 2026-01-27.
Status change: Recruiting → Active, Not Recruiting 2026-01-27
Status change: Not Yet Recruiting → Recruiting 2025-06-12
Trial Details
NCT Number NCT06993116
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Advanced Solid Tumor
Enrollment 15 participants
Start Date 2025-06-09
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-28